Record / 6 Nov 2026 / Research

Psilocybin research, 1958 to 2026

175 peer-reviewed studies, each summarized in plain English and linked to the paper itself. They are grouped by the condition studied, from depression to cluster headache, and you can filter by condition, study design, or decade.

Peer-reviewed studies and reviews of therapeutic psilocybin · updated 6 Nov 2026 · 175 records

Trials started each year

These bars count registered clinical trials, not the studies below. Every trial the register holds, by the year it began, so the shape is the field’s.

Start dates as filed with each registry; 5 of 343 trials state none6 Nov 2026 review

A further 11 trials are registered to start after 2026, and are not drawn.

Which trials are recruiting now →

9 trials began between 2004 and 2013; 74 started in 2026, the busiest year on the register.

Added in the latest review

6 Nov 2026

1 study was added on 6 Nov 2026, published in 2026.

2026 · naturalistic dataset of support-line interactions · n=25419

The Fireside Database releases 25,419 peer-support interactions handled by 220 trained volunteers on the Fireside Project's Psychedelic Support Line, a US service, between April 2021 and February 2026. It joins structured logs of each interaction with metadata coded by the volunteers and 2,777 caller satisfaction surveys scored on five outcome dimensions. Psilocybin was the substance most often reported, in 59.9% of the coded interactions, while cannabis carried the highest rate of distress, at 47.2%. Fifty supporters each completed at least ten surveyed interactions, which the authors say allows the effect of individual supporters on caller outcomes to be modelled. They present the dataset as a resource for psychedelic epidemiology, for the design of training and for asking what makes psychological support effective.

Science advances · Schoeller F et al.

Six studies to start with

6 landmark studies

Each with a line on why it matters. New to the evidence, start here; everything else is below.

All 175 studies

175 studies
Filter 175 studies
Condition
Study design
Access
Years

Depression and mood

22 studies · 125 trials →

2021 · RCT · n=59

Trial of Psilocybin versus Escitalopram for Depression

A 2021 phase 2, double-blind, randomized controlled trial (n=59) compared two sessions of psilocybin with a six-week course of the antidepressant escitalopram in adults with long-standing moderate-to-severe depression.

New England Journal of Medicine · Carhart-Harris R et al.

Cancer and end-of-life distress

18 studies · 17 trials →

2016 · RCT · n=51

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

In this randomized, double-blind crossover trial at Johns Hopkins, 51 people with life-threatening cancer and symptoms of depression and/or anxiety received a very low, placebo-like dose of psilocybin and a high dose in counterbalanced order, five weeks apart.

Journal of Psychopharmacology · Griffiths RR et al. · Free full text

2016 · RCT · n=29

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

In this double-blind, placebo-controlled crossover trial at New York University, 29 patients with cancer-related anxiety and depression were randomly assigned to a single dose of psilocybin (0.3 mg/kg) or niacin as a control, each paired with psychotherapy.

Journal of Psychopharmacology · Ross S et al. · Free full text

Addiction and substance use

14 studies · 46 trials →

2022 · RCT · n=95

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial

A 2022 double-blind randomized clinical trial (95 adults randomized, 93 treated) compared two psilocybin-assisted psychotherapy sessions (25-40 mg per 70 kg) against an active placebo (diphenhydramine), each combined with 12 psychotherapy sessions, in people with alcohol use disorder.

JAMA Psychiatry · Michael P. Bogenschutz et al. · Free full text

2026 · observational cohort study

Craving Reduction and Smoking Outcomes in Psilocybin-Assisted and Standard Cessation Care

An observational cohort compared smoking outcomes under psilocybin-assisted care and standard cessation care, sorting participants into a group whose smoking was driven mainly by dependence and a group whose smoking sat alongside affective symptoms.

Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · Strandberg L et al.

2026 · mixed quantitative and qualitative analysis of trial interviews · n=20

Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms

Twenty recently detoxified patients with alcohol use disorder and persisting depressive symptoms, all of them in the active psilocybin arm of a randomised trial, sat for a semi-structured integration interview the day after dosing.

Journal of affective disorders · Garcia Garcia M et al.

2025 · secondary analysis of a double-blind placebo-controlled trial · n=84

Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial

Eighty-four adults with alcohol use disorder were randomised to two medication sessions of either psilocybin or diphenhydramine as an active placebo, alongside twelve weekly psychotherapy sessions and a further twenty-four weeks of follow-up.

The American journal of psychiatry · Pagni BA et al.

OCD, headache, and eating disorders

17 studies

2026 · Open-label · n=21

Psilocybin therapy for adult females with anorexia nervosa: pilot study

A single-blind within-individual pilot in 21 adult females with anorexia nervosa, who received three fixed-order oral psilocybin doses (1 mg, 25 mg, 25 mg) over six weeks alongside talk therapy and treatment as usual.

The British Journal of Psychiatry · Douglass HM et al.

2025 · fixed-order pharmacological challenge study · n=19

Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study

Nineteen adults with obsessive compulsive disorder of at least moderate severity each received two single oral doses of psilocybin in a fixed order, a very small dose first and a larger one four weeks later, in a day care facility staffed by clinicians experienced in psychedelic treatment.

Comprehensive psychiatry · Pellegrini L et al.

2026 · RCT · n=9

Feasibility and Tolerability of Psilocybin for Phantom Limb Pain

A placebo-controlled, double-blind randomized pilot in nine people with one amputation and phantom limb pain, randomized to a single 25 mg oral dose of psilocybin (five participants) or 100 mg niacin (four).

The Journal of Pain · Dean JG et al.

2026 · longitudinal qualitative interview study within a trial · n=18

'So many relationships in the room': Participant perspectives on the affordances and challenges of co-therapy in psychedelic assisted therapy

Eighteen participants sampled from a large randomised, open-label phase 2 trial of psilocybin-assisted therapy for generalised anxiety disorder gave 29 semi-structured interviews before and after their dosing sessions, and the transcripts were analysed thematically.

Psychology and psychotherapy · Ham R et al.

2026 · Open-label · n=20

Pilot study of psilocybin in patients with post-treatment lyme disease

Twenty people with post-treatment Lyme disease, a chronic syndrome of fatigue, pain, cognitive difficulty and mood disturbance that follows antibiotic treatment in an estimated 10 to 20% of cases, took part in an open-label, single-arm pilot.

Scientific reports · Garcia-Romeu A et al.

2025 · qualitative interpretative phenomenological analysis within a trial · n=12

Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis

Twelve people were interviewed about a month after psilocybin dosing in what the authors describe as the first randomised placebo-controlled trial of a single psilocybin dose with unstructured, non-directive support for treatment-refractory obsessive compulsive disorder.

Frontiers in psychiatry · Ching THW et al.

2022 · RCT · n=14

Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial

A 2022 randomized, double-blind, placebo-controlled exploratory trial (n=14 analyzed) tested a patient-informed regimen of three low doses of psilocybin (0.143 mg/kg), given about five days apart, in people with cluster headache.

Headache: The Journal of Head and Face Pain · Emmanuelle A. D. Schindler et al.

1997 · Observational · n=1

Hallucinogen-induced relief of obsessions and compulsions

A 1997 single-patient case report in the American Journal of Psychiatry (filed as a letter) describing a person with obsessive-compulsive disorder who, the authors report, experienced temporary relief of obsessions and compulsions after taking psilocybin-containing mushrooms.

American Journal of Psychiatry · Francisco A. Moreno, Pedro L. Delgado

How it acts on the brain

38 studies

2026 · within-subject neuroimaging study (fMRI + EEG) · n=62

Psychedelics align brain activity with context

The authors report acquiring what they describe as the largest single-site psychedelic neuroimaging dataset to date.

Nature · Stoliker D et al.

2026 · Experimental · n=28

Multi-metric evaluations of acute psychedelic effects on fMRI brain entropy

An independent test of the theory that psychedelics increase brain entropy, evaluating 14 entropy metrics drawn from thirteen prior studies in a 28-participant healthy cohort with 121 pre- and post-psilocybin fMRI scans, across two parcellation strategies and seven denoising pipelines.

Nature Communications · McCulloch DE et al.

2026 · randomized crossover trial · n=20

A randomized crossover trial comparing the acute physiological and psychological effects of botanical formulations of oral psilocybin, oral psilocin, and sublingual psilocin

A randomized, within-subject crossover trial in 20 healthy adults (10 men, 10 women; mean age 40.1) comparing botanical whole-mushroom formulations across routes: oral psilocybin at 25 mg, oral psilocin at 17.5 mg, and sublingual psilocin at 2.18, 4.36 or 8 mg.

Journal of psychopharmacology (Oxford, England) · Tai ML et al.

2026 · Experimental · n=15

Psilocybin's effect on human brain synaptic plasticity

Fifteen healthy participants received a single 0.3 mg/kg dose of psilocybin either inside an MRI scanner or in a therapeutic-like room, with synaptic density measured via Synaptic Vesicle glycoprotein 2A using PET imaging in frontal cortex and hippocampus at baseline and one week after dosing.

Translational Psychiatry · Johansen A et al.

2026 · Experimental · n=28

Human brain changes after first psilocybin use

Twenty-eight healthy participants who had never taken a psychedelic received a 25 mg dose of psilocybin and a 1 mg dose used as a placebo, in an exploratory within-subject study with EEG and MRI from one hour to one month after dosing.

Nature communications · Lyons T et al.

2026 · double-blind placebo-controlled crossover EEG trial · n=20

Psilocybin-induced changes in electroencephalography link acute and long-term effects

Twenty healthy participants, half of them women, took part in a double-blind, placebo-controlled crossover trial with high-density resting-state electroencephalography recorded at baseline and at one, three, six and twenty-four hours after dosing, with a further follow-up four weeks later.

Journal of psychopharmacology (Oxford, England) · Nikolič M et al.

2024 · RCT · n=7

Psilocybin desynchronizes the human brain

This 2024 study used dense, repeated brain scanning (precision functional mapping, roughly 18 MRI sessions per person) in a small group of healthy adults who received a 25 mg dose of psilocybin and, on a separate visit, the stimulant methylphenidate as a comparison.

Nature · Joshua S. Siegel et al. · Free full text

2016 · Review

Psychedelics

This 2016 review by pharmacologist David E. Nichols is a widely cited, book-length survey of the serotonergic psychedelics, including psilocybin, LSD, mescaline and DMT.

Pharmacological Reviews, 68(2), 264-355 · David E. Nichols · Free full text

2014 · Review

The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs

This 2014 'Hypothesis and Theory' paper by Carhart-Harris and colleagues draws on psilocybin neuroimaging data to propose the 'entropic brain' hypothesis: that the richness of a conscious state can be indexed by the measurable entropy, or disorder, of spontaneous brain activity.

Frontiers in Human Neuroscience, Vol. 8, Article 20 · Robin L. Carhart-Harris et al. · Free full text

2012 · Survey · n=1602

Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin

A 2012 psychometric study that analyzed questionnaire data from 1,602 people who had taken psilocybin and reported a 4-factor structure underlying classic mystical-type experiences: unity/noetic quality/sacredness, positive mood, transcendence of time and space, and ineffability.

Journal for the Scientific Study of Religion · Katherine A. MacLean et al. · Free full text

2026 · mechanistic analysis of a randomised controlled trial · n=25

Mystical experiences mediate the effects of psilocybin-assisted psychotherapy + mindfulness-based stress reduction on trait mindfulness and depression symptoms: mechanistic results from a randomized controlled trial

Twenty-five frontline physicians and nurses with COVID-related depression were randomised to eight weeks of mindfulness-based stress reduction, on its own or with group psilocybin-assisted therapy at a 25 mg dose.

Journal of affective disorders reports · Byrne K et al.

2026 · longitudinal qualitative interview study within a trial · n=18

Participant Experiences of Therapeutic Touch in Psilocybin-Assisted Therapy

Eighteen participants in a large randomised trial of psilocybin-assisted therapy that permitted protocol-defined supportive touch gave 39 semi-structured interviews before and after dosing, covering what they expected of touch, what they experienced and how they read it afterwards.

Brain and behavior · Ham R et al.

2014 · Observational · n=15

Homological scaffolds of brain functional networks

In this 2014 study, Petri and colleagues applied topological data analysis to fMRI scans from healthy volunteers who received either placebo or intravenous psilocybin.

Journal of the Royal Society Interface, 11(101), 20140873 · Giovanni Petri et al. · Free full text

Safety and adverse events

49 studies

2026 · repeated cross-sectional survey across four countries

A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study

The 2023 International Cannabis Policy Study asked respondents in Canada, the United States, Australia and New Zealand about lifetime, past-year and past-month use of psilocybin, LSD, MDMA and ketamine, whether they had discussed such use with a medical professional...

The International journal on drug policy · Graham M et al.

2026 · pooled analysis of three studies, one a randomised controlled trial

Effects of psychedelic use on authoritarian attitudes revisited

The authors revisited the claim that psychedelic use lowers authoritarian attitudes, drawing on three studies with different designs and populations.

Journal of psychopharmacology (Oxford, England) · Simonsson O et al.

2008 · Review

Human hallucinogen research: guidelines for safety

A methods and safety review by Johns Hopkins researchers that proposes widely cited guidelines for conducting human studies with hallucinogens such as psilocybin.

Journal of Psychopharmacology · Matthew W. Johnson, William A. Richards, Roland R. Griffiths · Free full text

2026 · mailed and emailed attitude survey · n=49

Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice-Lessons Learned from a State Underrepresented in Clinical Psychedelic Research

A thirty-question survey was mailed and sent by digital newsletter to registered psychiatrists in Louisiana, asking how strongly they agreed with statements about psilocybin research, legalization, safety, addiction potential and medical use.

Psychedelic medicine (New Rochelle, N.Y.) · Husein A et al.

2026 · qualitative focus group study · n=4

Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network

Four members of the Psychedelic Participant Advocacy Network, all former trial participants, took part in three remote focus groups covering recruitment, preparation, dosing, integration and the end of a study.

Frontiers in psychiatry · Seynaeve M et al.

2026 · cross-sectional patient survey · n=202

Patient perspectives on research gaps in cluster headache

An online survey recruited Australian adults with self-reported cluster headache through clinicians, patient advocacy groups and social media, asking about treatment experience and what research they want.

Headache · Haghdoost F et al.

2026 · anonymous practitioner survey with thematic analysis · n=40

Provider perspectives on challenges in treatment during psychedelic therapy

An anonymous survey went by email to contacts listed on ClinicalTrials.gov for psilocybin and LSD trials, to the authors' own contacts and onward through snowball sampling, asking what goes wrong during psychedelic sessions.

Psychopharmacology · Bender DA et al.

2025 · latent class analysis of survey data · n=17977

Latent Classes of Lifetime Use of Seven Hallucinogens in the United States

A latent class analysis of 2021 and 2022 National Survey on Drug Use and Health data, restricted to the 17,977 respondents who reported ever using a hallucinogen, looked for patterns in which substances people had used.

Journal of psychoactive drugs · Meacham MC et al.

2025 · cross-sectional online survey · n=873

Perspectives on Trauma Treatment, Self-Management Strategies, and Attitudes Toward Psychedelic Therapies in Individuals with Psychological Trauma Symptoms

An online survey recruited people who reported trauma symptoms or carried a diagnosis of post-traumatic stress disorder or its complex form, and asked about their treatment history, how satisfied they were, and whether they used illicit substances to manage symptoms.

Psychiatry and clinical psychopharmacology · Modlin NL et al.

2025 · cross-sectional census of retail dispensaries with website content analysis

Psilocybin Dispensaries and Online Health Claims in Canada

Working from systematic web searches and media reports, the authors mapped the psilocybin dispensaries trading in Canada during May 2024, then read what those stores claimed online.

JAMA network open · Matsukubo J et al.

Reviews and meta-analyses

13 studies

2026 · systematic review · n=67

Subacute and long-term changes in cognitive functioning after administration of classic psychedelics, MDMA and ketamine: A systematic review of clinical and preclinical evidence

A systematic review of subacute and long-term effects, one day or more after dosing, of classic and non-classic psychedelics on executive function, attention and decision-making, drawing on 67 articles, 47 clinical and 20 preclinical, from MEDLINE, EMBASE, PsycInfo and Web of Science.

Neuroscience and Biobehavioral Reviews · Kelly C et al.

The early studies, 1958 to 1991

4 studies

1966 · Review

Implications of LSD and Experimental Mysticism

A 1966 theoretical paper in the Journal of Religion and Health in which Pahnke and Richards proposed a nine-category typology for describing mystical experience.

Journal of Religion and Health · Walter N. Pahnke, William A. Richards

For educational purposes only. Each summary reports what the cited study found and is not medical advice or an endorsement. This site makes no medical claims about psilocybin.

Links are checked by machine on a rolling basis. Some publishers block automated checks.